Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

PURPOSE: Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma. METHODS: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was admin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Batchelor, Tracy T., Duda, Dan G., di Tomaso, Emmanuelle, Ancukiewicz, Marek, Plotkin, Scott R., Gerstner, Elizabeth, Eichler, April F., Drappatz, Jan, Hochberg, Fred H., Benner, Thomas, Louis, David N., Cohen, Kenneth S., Chea, Houng, Exarhopoulos, Alexis, Loeffler, Jay S., Moses, Marsha A., Ivy, Percy, Sorensen, A. Gregory, Wen, Patrick Y., Jain, Rakesh K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903316/
https://ncbi.nlm.nih.gov/pubmed/20458050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.3988
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados